1. Home
  2. COUR vs SVRA Comparison

COUR vs SVRA Comparison

Compare COUR & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coursera Inc.

COUR

Coursera Inc.

HOLD

Current Price

$5.38

Market Cap

932.9M

Sector

Technology

ML Signal

HOLD

SVRA

Savara Inc.

HOLD

Current Price

$4.71

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COUR
SVRA
Founded
2012
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
932.9M
1.1B
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
COUR
SVRA
Price
$5.38
$4.71
Analyst Decision
Buy
Buy
Analyst Count
15
9
Target Price
$10.53
$7.33
AVG Volume (30 Days)
6.3M
1.2M
Earning Date
04-23-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
39.22
N/A
EPS
N/A
N/A
Revenue
$757,500,000.00
N/A
Revenue This Year
$9.43
N/A
Revenue Next Year
$6.40
$430.87
P/E Ratio
N/A
N/A
Revenue Growth
9.04
N/A
52 Week Low
$5.00
$1.89
52 Week High
$13.56
$7.01

Technical Indicators

Market Signals
Indicator
COUR
SVRA
Relative Strength Index (RSI) 44.28 36.26
Support Level $5.11 $3.36
Resistance Level $6.41 $6.15
Average True Range (ATR) 0.31 0.27
MACD -0.06 -0.03
Stochastic Oscillator 25.80 1.34

Price Performance

Historical Comparison
COUR
SVRA

About COUR Coursera Inc.

Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through two reporting segments: Consumer and Enterprise. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.

About SVRA Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Share on Social Networks: